ROSELLA phase III trial of relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer met its overall survival primary endpoint.
Scientists at The Wistar Institute have identified a mechanism behind the chemotherapy resistance that makes ovarian cancer so lethal. The researchers showed that chemotherapy triggers an inflammatory cascade that recruits immune cells into the tumor microenvironment, which ultimately function to protect the cancer from subsequent chemotherapy.
